# Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia

> **NCT02652793** · NA · COMPLETED · sponsor: **Judit Pich** · enrollment: 31 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **DRUG:** Boosted atazanavir
- **DRUG:** Lamivudine

## Key facts

- **NCT ID:** NCT02652793
- **Lead sponsor:** Judit Pich
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2018-11
- **Final completion:** 2018-11
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02652793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02652793, "Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02652793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*